Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sanofi SA (NASDAQ:GCVRZ)

0.25
Delayed Data
As of Jul 22
 +0.02 / +8.70%
Today’s Change
0.06
Today|||52-Week Range
0.60
+122.22%
Year-to-Date
Pharma Industry Outlook: Fundamentals Remain Strong
Jul 22 / Zacks.com - Paid Partner Content
Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week
Jul 20 / MotleyFool.com - Paid Partner Content
Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up
Jul 22 / Zacks.com - Paid Partner Content
Why Berkshire Hathaway Dumped Johnson & Johnson
Jul 19 / GuruFocus News - Paid Partner Content
Biogen Should Either a Buyer or a Seller Be
Jul 22 / TheStreet.com - Paid Partner Content
Pfizer Publishes Final Data from Atopic Dermatitis Studies
Jul 14 / Zacks.com - Paid Partner Content
Benzinga's M&A Chatter for Thursday July 21, 2016:
Jul 21 / Benzinga - Paid Partner Content
Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June
Jul 13 / MotleyFool.com - Paid Partner Content
Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
Jul 21 / TheStreet.com - Paid Partner Content
Better Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc.
Jul 12 / MotleyFool.com - Paid Partner Content
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Jul 21 / TheStreet.com - Paid Partner Content
Amgen's Repatha Gains FDA Approval for New Dosing Option
Jul 12 / Zacks.com - Paid Partner Content
Relypsa Finally Finds Buyer, But Potential Seen For Rival Bid
Jul 21 / TheStreet.com - Paid Partner Content
Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharm...
Jul 12 / MotleyFool.com - Paid Partner Content